Loading, Please Wait...
PHOENIX, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast welcomed SANUWAVE Health, Inc. (SNWV) (“the Company), a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. CEO and Chairman, Kevin A. Richardson, joined Stock Day host Everett Jolly.
To begin the interview Jolly asked Richardson to share the Company’s goals and expectations for 2019. Richardson explained that the Company’s flagship project is their dermaPACE product, which uses patented PACE technology to aid in the healing of diabetic foot ulcers. 2018 was a successful year for the Company and Richardson expects to expand into 100 treatment centers by the end of 2019. This would lead to a substantial increase in revenue.
“Our goal is to get a device anywhere and everywhere a diabetic foot ulcer is treated. If we do that, over the next few years, we’ll be a $100 million plus company,” stated Richardson. He continued by adding that the Company is in a unique situation where they can grow to high revenues while saving lives with their PACE technology.
Jolly then inquired about the Company’s international deals. Richardson explained that international sales are an extensive process, where revenue is usually present around year three. However, the Company is continuing to expand internationally and expects substantial growth from these partnerships.
When it comes to the Company’s expansion in the United States, Richardson explained that there are currently about 2,200 centers that treat diabetic foot ulcers. In 2019, the Company plans to be placed in 100 facilities, then 300-400 facilities in 2020, and eventually 2,000 by 2022.
Richardson further explained that the Company gets paid every time the device is used, so they are carefully planning their placement strategy based on reimbursement factors. He also stated that the Company plans to expand their use of the PACE technology to reach an even wider market and larger potential revenues.
Jolly then asked whether or not the device is leased to facilities, and if so, what kind of revenue this produces. Richardson explained that wound treatment centers can choose to purchase the device from the Company and then pay a fee each time the device is used, or they could lease the device for a monthly fee. Wound centers can also choose to pay a small monthly procedure fee. In general, the potential revenues for the Company could be up to $100 million with the dermaPACE device placed in 2,000 facilities.
To hear Kevin Richardson’s entire interview, follow the link to the podcast here: https://upticknewswire.com/featured-interview-ceo-kevin-richardson-of-sanuwave-health-inc-otcqb-snwv-6/
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE®, is currently under the FDA’s Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron®, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
Millennium Park Capital, LLC
SANUWAVE Health, Inc.
Kevin Richardson II
Chairman of the Board
About Uptick Newswire and the “Stock Day” Podcast
Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.